Stock Analiz

Vanda Pharmaceuticals Inc. VNDA

Biotechnology: Pharmaceutical Preparations · IPO 2006 · data as of November 13, 2026

$3.99Market cap $241M
Open the interactive analysis →

Vanda Pharmaceuticals Inc. (VNDA) is a healthcare company listed in the US with a market value of about $241M. In the twelve months to September 30, 2026 it had revenue of $229M and net income of -$275M, a net margin of -119.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -3% a year, a 5-year average ROIC of -7%.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2006. Revenue went from $50M in 2014 to $216M in 2025, growth of about 14.2% a year. It was profitable in 6 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 51% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.1
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-58.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)8.7%
Revenue growth (5 yrs, per year)-2.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-19.1%
ROIC (5-yr avg.)-7.4%
Profitable years (of last 10)6
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$229M$216M$199M$193M$254M$269M$248M$227M$193M$165M$146M
Net income-$275M-$220M-$19M$3M$6M$33M$23M$116M$25M-$16M-$18M
Free cash flow-$140M-$110M-$16M$12M$31M$64M$50M$45M$30M-$4M-$10M
EPS (diluted)$-4.62$-3.74$-0.33$0.04$0.11$0.58$0.42$2.11$0.48$-0.35$-0.41
Net margin-119.9%-102.0%-9.5%1.3%2.5%12.3%9.4%50.9%13.1%-9.4%-12.3%
ROIC—-35.9%-6.1%-2.0%0.7%6.4%4.3%4.2%7.8%-10.2%-11.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $11.50, 188% above the current price; targets range from $4.50 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-2.52 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Vanda Pharmaceuticals pay a dividend?

Not currently.

Is Vanda Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Vanda Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.